180
Participants
Start Date
January 1, 2026
Primary Completion Date
September 30, 2030
Study Completion Date
September 30, 2031
Semaglutide (Rybelsus®) combined with other interventions
The full intervention includes treatment with semaglutide (Rybelsus®) 3 mg daily for 4 weeks, followed by 7 mg daily for 4 weeks, and subsequently 14 mg daily. The intervention will also include candesartan up to 32 mg daily, a multivitamin-mineral tablet containing vitamin D and calcium, increased oral hygiene and a tooth lozenge (CariGuard®)
Placebo
A control group treated with placebo and no further intervention
Semaglutide (Rybelsus®)
An intervention group treated with semaglutide (Rybelsus®) 3 mg daily for 4 weeks followed by 7 mg daily for 4 weeks, hereafter 14 mg daily and placebo
Herlev Hospital
OTHER
Rune Skovgaard Rasmussen
OTHER